医药导报Issue(8)：987-992,6.DOI:10.3870/yydb.2015.08.001
利拉鲁肽用于超重和肥胖患者有效性的系统评价
Efficacy of Liraglutide for Obesity or Overweight:A Systematic Review
摘要
Abstract
Objective To evaluate the effectiveness and safety of liraglutide for obesity or overweight. Methods Random controlled trials of liraglutide for obesity or overweight were gathered from MEDLINE, EMbase, CENTRAL, CNKI, VIP and WanFang. We screened the retrieved studies according to the inclusion and exclusion criteria, evaluated the quality of included studies, and then performed meta-analyses with The Cochrane Collaboration's Revman 5. 3. 0 software. Results Twelve randomized controlled trials of liraglutide for obesity or overweight were included, in which 11 trials were written in English and one trial in Chinese. The results of meta-analyses showed that the body weight was significantly reduced in the liraglutide group than in placebo, insulin, exenatide and glimepiride groups [RR=-0. 91,95%CI(-1. 01,-0. 81),P<0. 000 01;RR=-2. 88,95%CI(-3. 37,-2. 39),P<0. 000 01; RR=-1. 12,95%CI(-1. 32,-0. 92),P<0. 000 01; RR=0. 45,95%CI(-0. 62,-0. 27),P<0. 000 01]. Moreover, liraglutide had significant effect in decreasing HbA1c and systolic blood pressure of patients with obesity or overweight. Conclusion Liraglutide is effective for controlling body weight of patients with obesity or overweight. But its long-term efficacy still needs to be confirmed by performing more RCTs with high quality, large sample and long term follow-up.关键词
利拉鲁肽/超重/肥胖/系统评价/Meta分析/对照试验,随机Key words
Liraglutide/Overweight/Obesity/Systematic review/Meta-analysis/Controlled trial, random分类
医药卫生引用本文复制引用
濮永杰,孔卫,徐珽..利拉鲁肽用于超重和肥胖患者有效性的系统评价[J].医药导报,2015,(8):987-992,6.基金项目
四川省预防医学会孵化项目(H1311112) （H1311112）
